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ABSTRACT 
Purpose: Antimuscarinic drugs increase bladder capacity without prominent side effects 
such as urinary retention even when administered to patients with mild to moderate 
BOO. Some mechanisms might exist in the urethra to compensate for the emptying 
function of the detrusor after administration of antimuscarinic drugs. We investigated 
the influences of an antimuscarinic drug, propiverine, on urethral function. 
Materials and Methods: Urethral pressure and rhythmic bladder pressure were 
simultaneously monitored in urethane-anesthetized female Sprague-Dawley rats. PGE2 
was continuously administered intravesically or intraurethrally to induce detrusor 
overactivity. Next, to eliminate the influence of bladder activity and to monitor urethral 
baseline pressure, isovolumetric pressure of the urethra was recorded after cystectomy 
and ligation of the external urethral meatus. Furthermore, the in vitro contractile 
responses of the urethral circular smooth muscle to field stimulation were examined in 
the presence of propiverine, tamsulosin, verapamil, ω-conotoxin, and atropine. 
Results: The intravesical or intraurethral administration of PGE2 significantly decreased 
bladder contraction interval (BCI) by 10.7% and 36.0%, respectively. The intraarterial 
administration of 2x102 nM/kg propiverine significantly increased BCI in rats receiving 
intraurethral PGE2 by 81.8%, but had no marked effect on rats receiving intravesical 
PGE2. Significant decreases in urethral baseline pressure were found after propiverine 
administration. Field stimulation-induced contraction was inhibited by propiverine and 
verapamil, but not by tamsulosin, ω-conotoxin or atropine. 
Conclusions: These results suggest that inhibitory effects of propiverine are more 
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prominent in rats with detrusor overactivity induced by intraurethral PGE2 than those by 
intravesical PGE2. Propiverine may compensate for detrusor function by decreasing 
urethral resistance in the voiding phase. 
 
INTRODUCTION 
   The efficacy of the systemic administration of antimuscarinic drugs to decrease the 
symptoms of the overactive bladder is well documented, and thought to be mainly due 
to their pronounced effects on the muscarinic receptors of the detrusor muscle. However, 
antimuscarinic drugs increase bladder capacity without prominent side effects such as 
urinary retention when administered to women or even to men with OAB and BOO.1 
Some mechanisms might exist in the urethra to compensate for the emptying 
dysfunction of the detrusor after the administration of antimuscarinic drugs. 
It has been shown that the innervation by fibers containing acetylcholinesterase is 
extensive in the normal human prostate gland.2,3 This cholinergic innervation has been 
reported to innervate only the smooth muscle surrounding the ducts and acini of the 
normal human prostate or both its glandular and stromal tissues.4,5 The location of these 
fibers suggests a role for acetylcholine in both contractility and secretion in the prostate 
gland. Acetylcholine caused contraction of prostatic smooth muscle from rabbits, pigs, 
rats, and guinea-pigs, but the response was less than that to α–adrenoceptor agonists.6,7 
Atropine has been reported to reduce contractions induced by field stimulation of nerves 
in prostate tissue isolated from guinea-pigs and rabbits.6,7 Therefore, antimuscarinic 
drugs have the possibility to reduce urethral resistance by decreasing prostate muscle 
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tonus. This may be the underlying mechanism in men to compensate for incomplete 
emptying after the administration of antimuscarinic drugs. Nevertheless, no reports 
could be found addressing the influences of antimuscarinic drugs on the urethral smooth 
muscle, especially in women.   
Antimuscarinic drugs act mainly during the storage phase, allowing an increase of 
the bladder capacity and decreasing urgency; therefore, they exert an inhibitory effect 
on bladder afferent nerves. We previously reported that a low dose of tolterodine, an 
antimuscarinic drug, exerted an inhibitory effect on C-fiber bladder afferents, improving 
bladder capacity in rats with cerebral infarction.8 However, DO can be induced by both 
bladder and urethral stimulation. Previous studies in rats have demonstrated that the 
intravesical or intraurethral administration of PGE2 resulted in detrusor overactivity.9 If 
antimuscarinic drugs can act on the urethra, could the inhibitory effect on C-fiber 
afferents be dependent on the urethra? To determine whether antimuscarinic drugs can 
act on the C-fiber afferents within the bladder or urethral wall, it is necessary to 
compare the effect of the drug on DO induced by stimulation of the bladder wall with 
that induced by stimulation of the urethral wall. We studied the influence of intraarterial 
propiverine, an antimuscarinic drug, on DO induced by the intravesical or intraurethral 
administration of PGE2.  
 
MATERIALS AND METHODS 
   A total of forty female Sprague-Dawley rats weighing 215-258 g (mean = 235 g) 
were used. They were housed at a constant temperature (23 ± 2ºC) and humidity 
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(50-60%) under a regular 12-h light/dark cycle (lights on 7:00 AM - 7:00 PM). Tap 
water and standard rat chow were freely available. All experiments were performed in 
strict accordance with the guidelines of the Institutional Animal Care and Use 
Committee of the University of Fukui.  
Simultaneous recordings of urethral and rhythmic bladder pressure 
   To induce desensitization of C-fiber afferent activity, we subcutaneously injected 
RTX (0.3 mg/kg) 2 days prior to the experiments. All surgical and urodynamic 
procedures were performed under urethane anesthesia (1.0 g/kg). The bladder and 
proximal urethra were exposed through a midline abdominal incision. Urethral activity, 
measured as the urethral perfusion pressure, was monitored using a polyethylene 
catheter (size 3; i.d. 0.5 mm, o.d. 1.0 mm; Kunii Co. Ltd., Tokyo, Japan) with the tip 
embedded in a cone-shaped plug that was introduced transvesically through an incision 
in the bladder dome and then seated securely in the bladder neck.9 The cone-shaped 
plug was fashioned from an Eppendorf pipette tip. The catheter end was then 
exteriorized at the external urethral meatus. To monitor intravesicular pressure, the 
bladder end of a catheter (size 4; i.d. 0.8 mm, o.d. 1.3 mm; Kunii Co. Ltd., Tokyo, 
Japan) was heated to create a collar and passed through the same incision of the bladder 
dome. This arrangement permitted the functional separation of bladder and urethral 
activity without the risk of surgical damage to the vesicourethral innervation associated 
with a urethral ligation or total urethrotomy. The bladder catheter was connected to a 
pump (TE-311; Terumo Co., Ltd., Tokyo, Japan) for infusion of physiological saline and 
to a pressure transducer (TP-200T; Nihon-Kohden Co., Ltd., Tokyo, Japan) by means of 
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a polyethylene T-tube. The urethral catheter was connected to a pump for continuous 
saline infusion (0.075 ml/min) and to a pressure transducer by means of a polyethylene 
T-tube.  
   After a 30-min postsurgical stabilization period, pressure recordings from the 
bladder and urethra were started. The bladder was filled with saline at a rate of 0.1 
ml/min to induce the micturition reflex, which was evident by rhythmic, 
large-amplitude bladder contractions. Bladder filling was then discontinued and 
isovolumetric pressure was recorded. The urethra was continuously infused with saline 
(0.075 ml/min). Thus, isovolumetric bladder and urethral perfusion pressure were 
recorded independently and simultaneously. The values of the two parameters, BCI and 
BCP were obtained from the micturition reflex measurements (fig. 1). 
   PGE2 (0.4 mg/ml) dissolved in 0.1 M phosphate buffer (pH 7.4) was continuously 
administered intravesically or intraurethrally to rats pretreated with RTX (RTX rats) or 
rats without pretreatment (non-RTX rats). The effects of propiverine hydrochloride 
(Taiho Pharm Co., Ltd., Tokyo, Japan) on the intravesical or intraurethral 
PGE2-stimulated micturition reflex were investigated at intraarterial doses of 2x102 or 
2x103 nM/kg. 
Urethral pressure measurement 
   To eliminate the influence of bladder activity and to monitor urethral baseline 
pressure, the isovolumetric pressure of the urethra was recorded after cystectomy and 
ligation of the external urethral meatus. The effects of propiverine (2x10 to 2x103 
nM/kg) on urethral baseline pressure were compared between the urethra filled with 
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PGE2 or 0.1 M phosphate buffer (vehicle).  
In vitro functional study 
   Circular smooth muscle strips were prepared from the middle part of the urethra. 
The urethra was cut into transverse circular preparations (width 1.5 mm, length 4 mm). 
Each segmental preparation was suspended vertically in an organ bath containing Krebs 
solution of the following composition (mmol/L); NaCl 111, KCl 5.90, CaCl2 2.50, 
MgCl2 1.20,  NaH2PO4 1.20, NaHCO3 25.0, and Glucose 11.5. The Krebs solution was 
continuously bubbled with a mixture of 95% O2 and 5% CO2 at 37C, resulting in a pH 
of 7.4. The preparations were suspended between two L-formed hooks. One of the 
hooks was connected to a movable unit allowing adjustment of tension of 0.5 gm. 
Changes in muscle tension were measured by an isometric transducer (TB-612T, 
Nihon-Kohden Co., Ltd., Tokyo, Japan). Transmural EFS was performed by a field 
stimulator (SEN-7203, Nihon-Kohden Co., Ltd.) delivering square wave pulses of 
supramaximal voltage and 0.5 msec. duration at a frequency of 50 Hz in 3 sec. trains at 
2 min. intervals. In order to study relaxant responses, the preparations were 
precontracted with the EFS. The contractile responses of the urethral circular smooth 
muscle to EFS were examined in the presence of propiverine, tamsulosin (α1-blocker; 
Taiho Pharm Co., Ltd., Tokyo, Japan), verapamil (an inhibitor of L-type 
voltage-operated calcium channels; Sigma, St. Louis), ω-conotoxin (an inhibitor of 
N-type voltage-operated calcium channels; Sigma, St. Louis), and atropine (Sigma, St. 
Louis). Relaxant responses were expressed as a percentage of the response obtained 
before application of the test drug. When the test drug reduced the contraction, the 
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percentage inhibitory ratio was calculated. The negative logarithm of the drug 
concentration eliciting half maximum inhibition (IC50) was determined by linear 
regression analysis. 
Data analysis 
   Data are expressed as the mean ± standard error of the mean (SEM). Statistical 
comparisons were performed using one- or two-way ANOVA with subsequent 
individual comparisons conducted using Fisher’s PLSD test. The two groups were 
compared using Mann Whitney’s U-test or Wilcoxon signed-ranks test. A level of p < 
0.05 was considered statistically significant. 
 
RESULTS 
BCI was markedly reduced after the intravesical or intraurethral administration of 
PGE2 in non-RTX rats (fig. 1), but was unchanged in RTX rats. The intravesical and 
intraurethral administration of PGE2 decreased the BCI by 10.7% and 36.0%, 
respectively, with these ratios expressed as 0% in fig. 2 as baseline ratios for the next 
experiment. The bladder contraction pressure was not changed before and after the 
intravesical or intraurethral administration of PGE2. 
Effects of intraarterial propiverine on PGE2-stimulated micturition reflex 
   The intraarterial administration of 2x102 nM/kg propiverine significantly increased 
BCI in rats receiving intraurethral PGE2 by 81.8% (p <0.05 vs control), but had no 
marked effects on rats receiving intravesical PGE2 (39.5%) or on rats receiving 
intraurethral 0.1 M phosphate buffer (30.0%)(fig. 2). A significant difference was found 
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in the changes in BCI between the rats receiving intraurethral and intravesical PGE2 (p 
<0.05). Propiverine significantly increased BCI at dose 2x103 nM/kg in both the rats 
receiving intraurethral and intravesical PGE2, whereas it had no effect on the rats 
receiving intraurethral 0.1 M phosphate buffer. Significant differences were found in the 
changes in BCI between the rats receiving intraurethral PGE2 and those receiving 
intraurethral 0.1 M phosphate buffer, and between the rats receiving intravesical PGE2 
and those receiving intraurethral 0.1 M phosphate buffer (both; p <0.05). Significant 
decreases in bladder contraction pressure were found after 2x103 nM/kg propiverine 
administration in the three treatment groups (p <0.05-0.01).  
Effects of intraarterial propiverine on urethral baseline pressure 
Urethral baseline pressure was compared between the urethra filled with PGE2 and 
0.1 M phosphate buffer (vehicle). A slight but significant decrease in urethral baseline 
pressure was found after 2x103 nM/kg propiverine administration (p <0.05, fig 3). 
In vitro functional study 
EFS induced contractions in the urethral circular smooth muscle at resting tension. A 
small tetorodotoxin (1x10-6 mol/L) abolished EFS-induced contraction. These 
contractions were significantly inhibited by propiverine (IC50 = 1.16 x 10-5 ml/L) and 
verapamil (IC50 = 1.43 x 10-5 ml/L), but not by tamsulosin, atropine or ω-conotoxin. 
 
DISCUSSION 
The data in the present study showed that the intraarterial administration of 
propiverine was found to have an inhibitory effect on detrusor overactivity when the 
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micturition reflex was overdriven by intravesical or intraurethral PGE2. The inhibitory 
effects of propiverine were more prominent in rats with detrusor overactivity induced by 
intraurethral PGE2 than those induced by intravesical PGE2. The effects of propiverine 
were accompanied by a decrease in urethral baseline pressure, which presumably 
depends on the calcium channel blocking effect of propiverine. These results support the 
hypothesis that propiverine improves detrusor overactivity by inhibition of bladder and 
urethral afferents.  
   Studies in rats and humans have demonstrated that the intravesical administration of 
PGE2 results in detrusor overactivity.10,11 PGE2 produces its endogenous activity via the 
EP receptor family of G protein-coupled receptors, of which four subtypes have been 
identified to date. The excitatory influences of PGE2 on the micturition reflex are 
attributable to the stimulation of C-fiber afferent nerves via the EP1 receptor.9 In a 
previous study using the same model as the present one, the excitatory effects on the 
micturition reflex produced by the intravesical administration of PGE2 were also seen in 
rats receiving intraurethral administration, but not in RTX-treated rats. The mechanism 
of these overactivities is unknown, but may be initiated by a PGE2–mediated increase in 
bladder or urethral C-fiber afferent activity.9 Pharmacological activation of urethral 
afferent nerves by intraurethral capsaicin elicited a biphasic change in micturition 
reflex,12 initially decreasing bladder contraction interval within minutes, followed 15 to 
30 min later by complete micturition reflex blockage. Barrington’s second reflex, 
urethral detrusor facilitative reflex, is believed to exist in this animal model. In the 
present study, propiverine had an inhibitory effect on the intraurethral or intravesical 
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PGE2-stimulated micturition reflex. These results have led us to hypothesize that 
propiverine exerts an inhibitory effect on C-fiber afferent nerves in the bladder and 
urethra. An antimuscarinic drug, tolterodine, has also been proven to improve detrusor 
overactivity caused by cerebral infarction through inhibition of the C-fiber bladder 
afferents.8 Propiverine had the same inhibitory effects on detrusor overactivity in rats 
with cerebral infarction (unpublished data). Therefore, the underlying mechanism by 
which propiverine suppresses C-fiber urethral afferents remains to be clarified. 
  It has been reported that the longitudinal smooth muscle layer of the female urethra is 
continuous with the longitudinal layer of the detrusor, implying a possible role in 
bladder neck opening and urethral shortening at the onset of voiding.12 The circular 
layer of the urethra is not continuous with the detrusor. It was suggested to be important 
for maintaining urethral closure and to be less sensitive to acetylcholine.13 The circular 
muscles of the human urethra have been reported to show a minimum or no response to 
muscarinic stimulation in vitro.14 Creed and Tulloch found that the increase in urethral 
pressure induced by pelvic nerve stimulation was resistant to α1-blocker and to 
atropine.15 Non-adrenergic and non-cholinergic contractions have been revealed in 
response to electrical stimulation of urethra isolated from rabbit, pig, and man, however, 
in the dog urethra an adrenergic contractions have been demonstrated.16 In the present 
study of the rat urethra contraction response of the circular muscle to EFS was not 
inhibited by atropine or tamsulosin, meaning non-adrenergic and non-cholinergic 
contractions. Further studies are necessary to confirm whether the contraction depends 
on purinergic transmission or not.  Furthermore, the contraction response to EFS was 
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not suppressed by ω-conotoxin (an inhibitor of N-type voltage-operated calcium 
channels), but was inhibited by propiverine and verapamil (an inhibitor of L-type 
voltage-operated calcium channels). The fact that, in the present study, propiverine 
inhibited the EFS-induced contractions of the circular muscle of the rat urethra may be 
explained by the blocking effect on the L-type voltage-operated calcium channel. 
Functionally, both propiverine and oxybutynin have been shown to be modulators of 
voltage-operated calcium channels.17 In addition to being a muscarinic receptor 
antagonist, propiverine has been reported to have an inhibitory effect on the L-type 
voltage-operated calcium channel.18 The effects of propiverine on the intraurethral 
PGE2-stimulated micturition reflex were considered to also be attributable to the action 
as an inhibitor of L-type voltage-operated calcium channels rather than to inhibition of 
the muscarinic receptor. In vivo and in vitro present studies revealed that propiverine 
had an inhibitory influence on urethral baseline pressure by the relaxant effect on the 
circular muscle of the urethra, and that the micturition reflex was then improved, when 
it had been overdriven by intraurethral PGE2. Taken together, these findings suggest that 
propiverine exerts an inhibitory effect on C-fiber urethral afferent nerves by decreasing 
urethral tonus and thereby improving storage symptoms. However, using 
urethane-treated animal increases the risk that effects of antimuscarinic drug will be 
masked by urethane anesthesia, since antimuscarinic drug influences the bladder or 
urethral afferent nerve activity.8 In order to really confirm C-fiber urethral afferent 
nerves, it is ideally necessary to record the activity from identified C-fibers. 
Antimuscarinic drugs are widely used to treat OAB symptoms, but the potential role 
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of antimuscarinic drugs for LUTS secondary to BPH has not been explored extensively. 
The development of therapies for male LUTS avoid urinary retention, for which patients 
with BPH are at high risk.19 Nevertheless, there are some reports suggesting that the 
inhibitory effect of antimuscarinic drugs on detrusor muscle contraction is unlikely to 
aggravate voiding dysfunction in men with OAB symptoms and possible BOO.1,20  
Although improvement in the urinary flow rate and a decrease in post-void residual 
volume were found, the underlying mechanisms to improve voiding dysfunction were 
not completely explained.19 An antimuscarinic drug, atropine, reduces contractions 
induced by the field stimulation of nerves in prostate tissue isolated from guinea-pigs 
and rabbits.6,7 An antimuscarinic drug, propiverine, has an effect on the L-type 
voltage-operated calcium channel, and may compensate for detrusor dysfunction by 
decreasing urethral resistance in the voiding phase. Antimuscarinic drugs have the 
possibility to reduce urethral resistance by decreasing prostatic and urethral muscle 
tonus. This is a hypothesis worthy of further study. 
 
CONCLUSIONS: The data in the present study suggest that at a low dose, propiverine 
exerts a relaxant effect on the urethral smooth muscle, thereby improving detrusor 
overactivity caused by intraurethral PGE2. Furthermore, this effect might diminish 
incomplete emptying by decreasing urethral resistance in patients with BOO. 
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FIGURE REGENDS 
Figure 1. Simultaneous recordings of isovolumetric bladder and urethral perfusion 
pressure before (A) and 10 min after (B) continuous intraurethral administration of 
PGE2. Intraurethral PGE2 facilitated rhythmic bladder contraction. Intraarterial 
administration of 2x102 nM/kg propiverine significantly increased bladder contraction 
interval (BCI). Bladder contraction pressure; BCP.   
 
Figure 2. Effects of intraarterial propiverine (2x102, 2x103 nM/kg) on bladder 
contraction interval (BCI)(A) and bladder contraction pressure (BCP)(B) in 
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urethane-anesthetized rats. The intravesical and intraurethral administration of PGE2 
significantly reduced BCI (circles and squares, respectively). The BCI values after the 
intravesical or intraurethral administration of PGE2 are expressed as 0%. Significant 
increases in BCI were recognized at 2 x 102 of propiverine in rats receiving intraurethral 
PGE2 when compared to rats receiving intravesical PGE2. No change in BCI was seen 
with increasing doses of propiverine in rats not receiving PGE2 (triangles). * indicates 
value of p <0.05, for indicated comparison. A high dose of propiverine (2 x 103 nM/kg) 
significantly decreased BCP when compared to the pre-administration value (control). # 
and ## indicate values of p <0.05 and 0.01, respectively, vs control. 
 
Figure 3. Effect of intraarterial propiverine on urethral baseline pressure in 
urethane-anesthetized rats with (circles) or without (triangles) the intraurethral 
administration of PGE2. Note that propiverine decreased the urethral baseline pressure 
in rats with an intraurethral administration of PGE2.  indicates value of p <0.05.  
 
Figure 4. Effects of compounds on the electrical field stimulation (EFS)-induced 
contraction of the urethral circular smooth muscle. This contraction was abolished by 1 
μM tetrodotoxin (open circle). Note that propiverine (circles) and verapamil (triangles) 
inhibited contractions to EFS, but tamsulosin(inverted triangles), ω-conotoxin (squares) 
and atropine (diamonds) did not.   
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